Arcosa (ACA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Jun, 2026Executive summary
Entered into a definitive agreement to be acquired by CRH for $8.5 billion, combining resources and expertise for future growth.
Announcement highlights pride in employee achievements and gratitude to customers and partners.
Transaction reflects a strategic milestone and is expected to benefit shareholders, employees, and customers.
Voting matters and shareholder proposals
Proxy statement will be filed with the SEC for a special meeting to solicit shareholder approval of the merger.
Shareholders are urged to review the proxy statement and related materials before voting.
Board of directors and corporate governance
Directors and executive officers may be deemed participants in the proxy solicitation for the merger.
Additional information on directors’ and officers’ interests will be disclosed in the proxy statement.
Latest events from Arcosa
- CRH’s $8.5B acquisition of Arcosa offers a 25% premium and accelerates infrastructure growth.ACA
Proxy filing22 Jun 2026 - Arcosa to be acquired by CRH for $8.5B, with shareholders receiving $150 per share.ACA
Proxy filing22 Jun 2026 - Definitive agreement for acquisition by CRH announced, pending shareholder approval in Q1 2027.ACA
Proxy filing22 Jun 2026 - CRH Americas to acquire Arcosa for $8.5B in cash, strengthening its U.S. infrastructure leadership.ACA
Proxy filing22 Jun 2026 - Streamlined portfolio and raised 2026 outlook driven by strong infrastructure demand.ACA
Investor presentation8 Jun 2026 - Q1 2026 Adjusted EBITDA up 10%, guidance raised, and barge divestiture boosted liquidity.ACA
Q1 20261 May 2026 - Vote on nine directors, executive pay, and auditor ratification at the May 2026 meeting.ACA
Proxy filing31 Mar 2026 - Record financial results, strong governance, and sustainability milestones highlighted.ACA
Proxy filing31 Mar 2026 - Record 2025 growth, barge divestiture, and strong 2026 EBITDA outlook with margin expansion.ACA
Q4 202527 Feb 2026